上睑下垂
炎症体
结肠炎
半胱氨酸蛋白酶1
化学
细胞生物学
调制(音乐)
医学
免疫学
生物
生物化学
受体
物理
声学
作者
Ranjeny Thomas,Qianqian Di,Xiaoli Li,Xibao Zhao,Ruihan Zhang,Yong Xiao,Xunwei Li,Han Wu,Honglei Tang,Jiazheng Quan,Zherui Wu,Wei‐Lie Xiao,Weilin Chen
标识
DOI:10.3389/fimmu.2022.853194
摘要
Inflammatory bowel diseases (IBDs) are increasingly common diseases characterized by chronic and relapsing inflammation of the gastrointestinal tract. NLRP3 might be a crucial regulator of the homeostatic balance of the intestine, but its upregulation leads to pyroptosis. Munronoid I is extracted and purified from Munronia sinica , which has shown an anti-inflammatory effect, but the efficacy of Munronoid I in IBD remains unproven. In this study, we attempted to determine the effect of Munronoid I on NLRP3 to regulate the inflammasome activation and pyroptosis in IBD. Our data demonstrated that Munronoid I treatment attenuated DSS-induced body weight loss, pathological injury of the colon, the production of IL-1β and IL-18, and the expression of pyroptosis-associated proteins in colon tissue in mice. Moreover, Munronoid I inhibited LPS/ATP-induced pyroptosis in mouse peritoneal macrophages, MODE-K cells, and DSS-induced pyroptosis in mouse colonic epithelial cells, and decreased the release of inflammatory cytokines IL-1β and IL-18 in mouse peritoneal macrophages. Mechanically, Munronoid I could suppress the NLRP3 inflammasome activation and pyroptosis by promoting the K48-linked ubiquitination and NLRP3 degradation. It is suggested that Munronoid I might be a potential therapeutic candidate for IBD.
科研通智能强力驱动
Strongly Powered by AbleSci AI